Advanced search
Publication Cover
Modern Rheumatology Volume 25, 2015 - Issue 1
Journal homepage
1,703
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies

Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, JapanCorrespondence[email protected]
,
Kazuhiko YamamotoDepartment of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
,
Hisashi YamanakaInstitute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan
,
Naoki IshiguroDepartment of Orthopedic Surgery, Nagoya University Graduate School and Faculty of Medicine, Nagoya, Aichi, Japan
,
Yoshiya TanakaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
,
Katsumi EguchiSasebo City General Hospital, Sasebo, Nagasaki, Japan
,
Akira WatanabeResearch Division for Development of Anti-Infectious Agents, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan
,
Hideki OrigasaDivision of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan
,
Toshiharu ShojiDepartment of Clinical Research and Development, UCB Japan Co., Ltd., Shinjuku-ku, Tokyo, Japan
,
Nobuyuki MiyasakaDepartment of Medicine and Rheumatology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
&
Takao KoikeNTT Sapporo Medical Center, Sapporo, Hokkaido, Japan
 show all
Pages 11-20 | Received 17 Jan 2014, Accepted 12 Mar 2014, Published online: 20 May 2014

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Tomohiro Kubota, Syuji Takei, Masaki Shimizu, Junko Yasumura, Yasuo Nakagishi, Toshitaka Kizawa, Masato Yashiro, Hiroyuki Wakiguchi, Yuichi Yamasaki & Yoshifumi Kawano. (2018) Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan. Modern Rheumatology 28:5, pages 826-831.
Read now
Tsutomu Takeuchi, Kazuhiko Yamamoto, Hisashi Yamanaka, Naoki Ishiguro, Yoshiya Tanaka, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Mariko Kobayashi, Toshiharu Shoji, Osamu Togo, Nobuyuki Miyasaka & Takao Koike. (2016) analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Modern Rheumatology 26:4, pages 473-480.
Read now

Articles from other publishers (8)

Zhuqian Wang, Jie Huang, Duoli Xie, Dongyi He, Aiping Lu & Chao Liang. (2021) Toward Overcoming Treatment Failure in Rheumatoid Arthritis. Frontiers in Immunology 12.
Crossref
Xin Wu, Xiaobao Sheng, Rong Sheng, Hongjuan Lu & Huji Xu. (2019) Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis. Frontiers of Medicine 13:4, pages 411-419.
Crossref
Enrique R Soriano, Analia Dellepiane, Gabriela Salvatierra, Cristian Alejandro Benítez, Rodrigo Garcia Salinas & Carlos Baruzzo. (2018) Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. Future Science OA 4:4, pages FSO289.
Crossref
Florenzo Iannone, Giorgio Carlino, Antonio Marchesoni, Piercarlo Sarzi-Puttini, Roberto Gorla & Giovanni Lapadula. (2017) Polyarthrite rhumatoïde : réponse clinique précoce sous certolizumab prédictive d’une faible activité de la maladie à un an en situation de “vraie vie”. Évaluation du registre italien GISEA. Revue du Rhumatisme 84:6, pages 511-515.
Crossref
Erkki Soini, Christian Asseburg, Maarit Taiha, Kari Puolakka, Oana Purcaru & Riitta Luosujärvi. (2017) Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland. Advances in Therapy 34:10, pages 2316-2332.
Crossref
D. van der Heijde, A. Deodhar, R. Fleischmann, P. J. Mease, M. Rudwaleit, T. Nurminen & O. Davies. (2017) Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis. Arthritis Care & Research 69:7, pages 1030-1039.
Crossref
Florenzo Iannone, Giorgio Carlino, Antonio Marchesoni, Piercarlo Sarzi-Puttini, Roberto Gorla & Giovanni Lapadula. (2016) Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA. Joint Bone Spine 83:6, pages 721-725.
Crossref
Daniel Aletaha, Farideh Alasti & Josef S Smolen. (2016) Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Annals of the Rheumatic Diseases 75:8, pages 1479-1485.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.